| Code | CSB-RA023984MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to PE-0116, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as CD137 or 4-1BB. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a crucial role in T cell proliferation, survival, and cytotoxic function. Upon binding its ligand 4-1BBL, TNFRSF9 delivers potent stimulatory signals that enhance anti-tumor immune responses and promote immunological memory. This receptor has emerged as a significant therapeutic target in immuno-oncology, with relevance to cancer immunotherapy, autoimmune diseases, and viral infections.
As a biosimilar to the reference antibody PE-0116, this antibody provides researchers with a reliable tool for investigating TNFRSF9 biology and immune checkpoint modulation. It is particularly valuable for studies exploring T cell activation mechanisms, tumor microenvironment dynamics, and the development of agonistic immunotherapeutic strategies. This product supports diverse immunology research applications aimed at understanding costimulatory signaling pathways and their therapeutic potential.
There are currently no reviews for this product.